BTIG analyst Ryan Zimmerman maintained a Buy rating on Vericel (VCEL – Research Report) today and set a price target of $53.00. The company’s shares closed yesterday at $48.13.
Zimmerman covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, RxSight, and GE Healthcare Technologies Inc. According to TipRanks, Zimmerman has an average return of 12.3% and a 50.41% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vericel with a $48.10 average price target.
See today’s best-performing stocks on TipRanks >>
Based on Vericel’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $45.58 million and a GAAP net loss of $3.66 million. In comparison, last year the company earned a revenue of $38.55 million and had a GAAP net loss of $6.58 million
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vericel (VCEL) Company Description:
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Read More on VCEL:
- Vericel price target raised to $53 from $49 at BTIG
- Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
- Vericel price target raised to $49 from $41 at BTIG
- Tesla, Boeing downgraded: Wall Street’s top analyst calls
